Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Metastasis, Broad-Spectrum Antiviral, and ADC Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Annexin A2 drug discovery. The following table consolidates all available product components from multiple validated sources.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANXA2 Full-Length Recombinant Protein; High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. Domain variants also available. | View ANXA2 Products |
| Complex Partner | ANXA2-S100A10 Heterotetramer Complex; Native complex formation verified by Co-IP. Critical for functional assays and PPI inhibition studies. | View ANXA2 Products |
| Gene Delivery | ANXA2 Promise-ORF Lentivirus; Full-length ORF for stable cell lines. CMV promoter, Puromycin selection. | View ANXA2 Products |
| Positive Control / Benchmark Ab | Anti-ANXA2 Monoclonal Antibody (Clone DXL-1); Recombinant research-grade positive control for assay validation and standardization. | View ANXA2 Products |
| Validator | ANXA2 siRNA Set (3 unique sequences); For knockdown verification and specificity controls. | View ANXA2 Products |
| Related Target: S100A10 | S100A10 (p11) Recombinant Protein; Obligate binding partner for ANXA2 surface translocation and heterotetramer formation. | View S100A10 Products |
| Related Target: PLG | Plasminogen (PLG) Protein; Direct interacting partner for ANXA2; target for metastasis, fibrinolysis, and neoangiogenesis bypass. | View PLG Products |
Technical Specifications for Critical Assays
This table combines assay challenges and TarMart advantages from multiple expert sources.
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-Dependent Conformational Screening | Buffer-optimized proteins (Ca2+ responsive). Theoretical MW verified by MS. Activity contingent on calcium-binding domains. Apo and holo forms available. |
| Cell Surface vs. Intracellular Epitope Mapping | Live cell staining compatible. Non-permeabilized flow cytometry validation with lentivirus-transduced stable lines. High purity (>95%) ECD and full-length proteins structurally preserved. |
| S100A10 Heterotetramer Disruption (PPI Inhibition) | Pre-formed complex available for competition assays. SPR/BLI ready format. Sequence-verified interacting partners expressed in HEK293 for native folding. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity. Sequence identity >90% verified by mass spec. |
| False Positive Control & Background Noise | Validated siRNA included for specificity checks. Calcium-binding site mutants available. Benchmark recombinant antibodies for assay standardization. |
| Phosphorylation-State Dependent Epitope Exposure (Tyr23) | Phospho-mimetic (Y23E) and phospho-dead (Y23F) mutant proteins available for epitope mapping and kinase inhibitor synergy studies. |
Live ANXA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for Annexin A2 (ANXA2) therapeutics is intensifying, with major players shifting focus from traditional cytotoxics to metastasis-blocking biologics, broad-spectrum antivirals, and Antibody-Drug Conjugates (ADCs). As first-generation anti-metastatic antibodies enter Phase I, the next wave of R&D is targeting the tumor-specific ANXA2-S100A10 complex to mitigate off-target bleeding risks associated with systemic plasminogen interference. Overexpressed on the surface of various solid tumors (including pancreatic, breast, and glioblastoma) while remaining largely intracellular in normal tissues, ANXA2 presents a unique therapeutic window.
Current development highlights include:
- Oncology: ANXA2 surface blockade to inhibit plasminogen activation and metastatic extravasation; ADC development for ANXA2+ cancers.
- Infectious Disease: Viral entry inhibition (Influenza, Ebola, SARS-CoV-2) via membrane fusion disruption.
- Hematology / Vascular: Anticoagulant strategies targeting the ANXA2-tPA-plasminogen axis.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Surface Blockade) | Academic Consortia, Biotech, Spin-offs | Solid Tumors (Metastatic, Pancreatic, Glioblastoma) | Cell Surface Binding Assay (Need full-length native protein and S100A10/ANXA2 complexes for live cell staining and selectivity). |
| Antibody-Drug Conjugate (ADC) | Emerging Oncology Biotechs | Triple-Negative Breast Cancer (TNBC), ANXA2+ Cancers | Internalization Assay (Need high-purity antigen for pH-dependent release testing and lentivirus for high-expression stable cell lines). |
| Peptide Inhibitor (PPI Disruptor) | Early Discovery | Fibrosis, Metastasis | Heterotetramer Disruption (Need ANXA2-S100A10 complex for SPR competition and complex stability assays). |
| Small Molecule (Ca2+ Binding or Allosteric) | Preclinical | Viral Infection, Refractory Solid Tumors, Neovascularization | Calcium-Dependent Conformation Shift (Need apo vs. holo protein forms for SPR/BLI screening). |